Drugs for Non-small Cell Lung Cancer-Global Market Status and Trend Report 2013-2023
Report Summary
Drugs for Non-small Cell Lung Cancer-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Drugs for Non-small Cell Lung Cancer industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Drugs for Non-small Cell Lung Cancer 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Drugs for Non-small Cell Lung Cancer worldwide, with company and product introduction, position in the Drugs for Non-small Cell Lung Cancer market
Market status and development trend of Drugs for Non-small Cell Lung Cancer by types and applications
Cost and profit status of Drugs for Non-small Cell Lung Cancer, and marketing status
Market growth drivers and challenges
The report segments the global Drugs for Non-small Cell Lung Cancer market as:
Global Drugs for Non-small Cell Lung Cancer Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Drugs for Non-small Cell Lung Cancer Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Global Drugs for Non-small Cell Lung Cancer Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinic
Other
Global Drugs for Non-small Cell Lung Cancer Market: Manufacturers Segment Analysis (Company and Product introduction, Drugs for Non-small Cell Lung Cancer Sales Volume, Revenue, Price and Gross Margin):
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Drugs for Non-small Cell Lung Cancer-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Drugs for Non-small Cell Lung Cancer industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Drugs for Non-small Cell Lung Cancer 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Drugs for Non-small Cell Lung Cancer worldwide, with company and product introduction, position in the Drugs for Non-small Cell Lung Cancer market
Market status and development trend of Drugs for Non-small Cell Lung Cancer by types and applications
Cost and profit status of Drugs for Non-small Cell Lung Cancer, and marketing status
Market growth drivers and challenges
The report segments the global Drugs for Non-small Cell Lung Cancer market as:
Global Drugs for Non-small Cell Lung Cancer Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Drugs for Non-small Cell Lung Cancer Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Global Drugs for Non-small Cell Lung Cancer Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinic
Other
Global Drugs for Non-small Cell Lung Cancer Market: Manufacturers Segment Analysis (Company and Product introduction, Drugs for Non-small Cell Lung Cancer Sales Volume, Revenue, Price and Gross Margin):
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF DRUGS FOR NON-SMALL CELL LUNG CANCER
1.1 Definition of Drugs for Non-small Cell Lung Cancer in This Report
1.2 Commercial Types of Drugs for Non-small Cell Lung Cancer
1.2.1 Radiofrequency Ablation (RFA)
1.2.2 Radiation Therapy
1.2.3 Chemotherapy
1.2.4 Targeted Therapies
1.2.5 Immunotherapy
1.3 Downstream Application of Drugs for Non-small Cell Lung Cancer
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Other
1.4 Development History of Drugs for Non-small Cell Lung Cancer
1.5 Market Status and Trend of Drugs for Non-small Cell Lung Cancer 2013-2023
1.5.1 Global Drugs for Non-small Cell Lung Cancer Market Status and Trend 2013-2023
1.5.2 Regional Drugs for Non-small Cell Lung Cancer Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Drugs for Non-small Cell Lung Cancer 2013-2017
2.2 Sales Market of Drugs for Non-small Cell Lung Cancer by Regions
2.2.1 Sales Volume of Drugs for Non-small Cell Lung Cancer by Regions
2.2.2 Sales Value of Drugs for Non-small Cell Lung Cancer by Regions
2.3 Production Market of Drugs for Non-small Cell Lung Cancer by Regions
2.4 Global Market Forecast of Drugs for Non-small Cell Lung Cancer 2018-2023
2.4.1 Global Market Forecast of Drugs for Non-small Cell Lung Cancer 2018-2023
2.4.2 Market Forecast of Drugs for Non-small Cell Lung Cancer by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Drugs for Non-small Cell Lung Cancer by Types
3.2 Sales Value of Drugs for Non-small Cell Lung Cancer by Types
3.3 Market Forecast of Drugs for Non-small Cell Lung Cancer by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Drugs for Non-small Cell Lung Cancer by Downstream Industry
4.2 Global Market Forecast of Drugs for Non-small Cell Lung Cancer by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Drugs for Non-small Cell Lung Cancer Market Status by Countries
5.1.1 North America Drugs for Non-small Cell Lung Cancer Sales by Countries (2013-2017)
5.1.2 North America Drugs for Non-small Cell Lung Cancer Revenue by Countries (2013-2017)
5.1.3 United States Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
5.1.4 Canada Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
5.1.5 Mexico Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
5.2 North America Drugs for Non-small Cell Lung Cancer Market Status by Manufacturers
5.3 North America Drugs for Non-small Cell Lung Cancer Market Status by Type (2013-2017)
5.3.1 North America Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)
5.3.2 North America Drugs for Non-small Cell Lung Cancer Revenue by Type (2013-2017)
5.4 North America Drugs for Non-small Cell Lung Cancer Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Drugs for Non-small Cell Lung Cancer Market Status by Countries
6.1.1 Europe Drugs for Non-small Cell Lung Cancer Sales by Countries (2013-2017)
6.1.2 Europe Drugs for Non-small Cell Lung Cancer Revenue by Countries (2013-2017)
6.1.3 Germany Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.1.4 UK Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.1.5 France Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.1.6 Italy Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.1.7 Russia Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.1.8 Spain Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.1.9 Benelux Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.2 Europe Drugs for Non-small Cell Lung Cancer Market Status by Manufacturers
6.3 Europe Drugs for Non-small Cell Lung Cancer Market Status by Type (2013-2017)
6.3.1 Europe Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)
6.3.2 Europe Drugs for Non-small Cell Lung Cancer Revenue by Type (2013-2017)
6.4 Europe Drugs for Non-small Cell Lung Cancer Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Drugs for Non-small Cell Lung Cancer Market Status by Countries
7.1.1 Asia Pacific Drugs for Non-small Cell Lung Cancer Sales by Countries (2013-2017)
7.1.2 Asia Pacific Drugs for Non-small Cell Lung Cancer Revenue by Countries (2013-2017)
7.1.3 China Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
7.1.4 Japan Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
7.1.5 India Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
7.1.6 Southeast Asia Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
7.1.7 Australia Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
7.2 Asia Pacific Drugs for Non-small Cell Lung Cancer Market Status by Manufacturers
7.3 Asia Pacific Drugs for Non-small Cell Lung Cancer Market Status by Type (2013-2017)
7.3.1 Asia Pacific Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)
7.3.2 Asia Pacific Drugs for Non-small Cell Lung Cancer Revenue by Type (2013-2017)
7.4 Asia Pacific Drugs for Non-small Cell Lung Cancer Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Drugs for Non-small Cell Lung Cancer Market Status by Countries
8.1.1 Latin America Drugs for Non-small Cell Lung Cancer Sales by Countries (2013-2017)
8.1.2 Latin America Drugs for Non-small Cell Lung Cancer Revenue by Countries (2013-2017)
8.1.3 Brazil Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
8.1.4 Argentina Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
8.1.5 Colombia Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
8.2 Latin America Drugs for Non-small Cell Lung Cancer Market Status by Manufacturers
8.3 Latin America Drugs for Non-small Cell Lung Cancer Market Status by Type (2013-2017)
8.3.1 Latin America Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)
8.3.2 Latin America Drugs for Non-small Cell Lung Cancer Revenue by Type (2013-2017)
8.4 Latin America Drugs for Non-small Cell Lung Cancer Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Drugs for Non-small Cell Lung Cancer Market Status by Countries
9.1.1 Middle East and Africa Drugs for Non-small Cell Lung Cancer Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Drugs for Non-small Cell Lung Cancer Revenue by Countries (2013-2017)
9.1.3 Middle East Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
9.1.4 Africa Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
9.2 Middle East and Africa Drugs for Non-small Cell Lung Cancer Market Status by Manufacturers
9.3 Middle East and Africa Drugs for Non-small Cell Lung Cancer Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)
9.3.2 Middle East and Africa Drugs for Non-small Cell Lung Cancer Revenue by Type (2013-2017)
9.4 Middle East and Africa Drugs for Non-small Cell Lung Cancer Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF DRUGS FOR NON-SMALL CELL LUNG CANCER
10.1 Global Economy Situation and Trend Overview
10.2 Drugs for Non-small Cell Lung Cancer Downstream Industry Situation and Trend Overview
CHAPTER 11 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Drugs for Non-small Cell Lung Cancer by Major Manufacturers
11.2 Production Value of Drugs for Non-small Cell Lung Cancer by Major Manufacturers
11.3 Basic Information of Drugs for Non-small Cell Lung Cancer by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Drugs for Non-small Cell Lung Cancer Major Manufacturer
11.3.2 Employees and Revenue Level of Drugs for Non-small Cell Lung Cancer Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 DRUGS FOR NON-SMALL CELL LUNG CANCER MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Bristol-Myers Squibb
12.1.1 Company profile
12.1.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.1.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
12.2 GlaxoSmithKline
12.2.1 Company profile
12.2.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.2.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.3 Menarini
12.3.1 Company profile
12.3.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.3.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Menarini
12.4 Sanofi
12.4.1 Company profile
12.4.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.4.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Sanofi
12.5 Ziopharm Oncology
12.5.1 Company profile
12.5.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.5.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Ziopharm Oncology
12.6 Alchemia
12.6.1 Company profile
12.6.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.6.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Alchemia
12.7 Amgen
12.7.1 Company profile
12.7.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.7.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Amgen
12.8 Apotex
12.8.1 Company profile
12.8.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.8.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Apotex
12.9 BioMarin Pharmaceutical
12.9.1 Company profile
12.9.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.9.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of BioMarin Pharmaceutical
12.10 CellAct Pharma
12.10.1 Company profile
12.10.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.10.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of CellAct Pharma
12.11 Cerulean Pharma
12.11.1 Company profile
12.11.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.11.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Cerulean Pharma
12.12 Cipla
12.12.1 Company profile
12.12.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.12.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Cipla
12.13 Cornerstone Pharmaceuticals
12.13.1 Company profile
12.13.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.13.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Cornerstone Pharmaceuticals
12.14 Curis
12.14.1 Company profile
12.14.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.14.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Curis
12.15 CytRx
12.15.1 Company profile
12.15.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.15.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of CytRx
12.16 Eli Lilly
12.17 Exelixis
12.18 Fresenius Kabi
12.19 Genentech
12.20 Hikma Pharmaceuticals
12.21 Hospira
12.22 Intas Pharmaceuticals
12.23 Karyopharm Therapeutics
12.24 Kyowa Hakko Kirin
12.25 Ligand Pharmaceuticals
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF DRUGS FOR NON-SMALL CELL LUNG CANCER
13.1 Industry Chain of Drugs for Non-small Cell Lung Cancer
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF DRUGS FOR NON-SMALL CELL LUNG CANCER
14.1 Cost Structure Analysis of Drugs for Non-small Cell Lung Cancer
14.2 Raw Materials Cost Analysis of Drugs for Non-small Cell Lung Cancer
14.3 Labor Cost Analysis of Drugs for Non-small Cell Lung Cancer
14.4 Manufacturing Expenses Analysis of Drugs for Non-small Cell Lung Cancer
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Drugs for Non-small Cell Lung Cancer in This Report
1.2 Commercial Types of Drugs for Non-small Cell Lung Cancer
1.2.1 Radiofrequency Ablation (RFA)
1.2.2 Radiation Therapy
1.2.3 Chemotherapy
1.2.4 Targeted Therapies
1.2.5 Immunotherapy
1.3 Downstream Application of Drugs for Non-small Cell Lung Cancer
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Other
1.4 Development History of Drugs for Non-small Cell Lung Cancer
1.5 Market Status and Trend of Drugs for Non-small Cell Lung Cancer 2013-2023
1.5.1 Global Drugs for Non-small Cell Lung Cancer Market Status and Trend 2013-2023
1.5.2 Regional Drugs for Non-small Cell Lung Cancer Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Drugs for Non-small Cell Lung Cancer 2013-2017
2.2 Sales Market of Drugs for Non-small Cell Lung Cancer by Regions
2.2.1 Sales Volume of Drugs for Non-small Cell Lung Cancer by Regions
2.2.2 Sales Value of Drugs for Non-small Cell Lung Cancer by Regions
2.3 Production Market of Drugs for Non-small Cell Lung Cancer by Regions
2.4 Global Market Forecast of Drugs for Non-small Cell Lung Cancer 2018-2023
2.4.1 Global Market Forecast of Drugs for Non-small Cell Lung Cancer 2018-2023
2.4.2 Market Forecast of Drugs for Non-small Cell Lung Cancer by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Drugs for Non-small Cell Lung Cancer by Types
3.2 Sales Value of Drugs for Non-small Cell Lung Cancer by Types
3.3 Market Forecast of Drugs for Non-small Cell Lung Cancer by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Drugs for Non-small Cell Lung Cancer by Downstream Industry
4.2 Global Market Forecast of Drugs for Non-small Cell Lung Cancer by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Drugs for Non-small Cell Lung Cancer Market Status by Countries
5.1.1 North America Drugs for Non-small Cell Lung Cancer Sales by Countries (2013-2017)
5.1.2 North America Drugs for Non-small Cell Lung Cancer Revenue by Countries (2013-2017)
5.1.3 United States Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
5.1.4 Canada Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
5.1.5 Mexico Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
5.2 North America Drugs for Non-small Cell Lung Cancer Market Status by Manufacturers
5.3 North America Drugs for Non-small Cell Lung Cancer Market Status by Type (2013-2017)
5.3.1 North America Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)
5.3.2 North America Drugs for Non-small Cell Lung Cancer Revenue by Type (2013-2017)
5.4 North America Drugs for Non-small Cell Lung Cancer Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Drugs for Non-small Cell Lung Cancer Market Status by Countries
6.1.1 Europe Drugs for Non-small Cell Lung Cancer Sales by Countries (2013-2017)
6.1.2 Europe Drugs for Non-small Cell Lung Cancer Revenue by Countries (2013-2017)
6.1.3 Germany Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.1.4 UK Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.1.5 France Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.1.6 Italy Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.1.7 Russia Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.1.8 Spain Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.1.9 Benelux Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
6.2 Europe Drugs for Non-small Cell Lung Cancer Market Status by Manufacturers
6.3 Europe Drugs for Non-small Cell Lung Cancer Market Status by Type (2013-2017)
6.3.1 Europe Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)
6.3.2 Europe Drugs for Non-small Cell Lung Cancer Revenue by Type (2013-2017)
6.4 Europe Drugs for Non-small Cell Lung Cancer Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Drugs for Non-small Cell Lung Cancer Market Status by Countries
7.1.1 Asia Pacific Drugs for Non-small Cell Lung Cancer Sales by Countries (2013-2017)
7.1.2 Asia Pacific Drugs for Non-small Cell Lung Cancer Revenue by Countries (2013-2017)
7.1.3 China Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
7.1.4 Japan Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
7.1.5 India Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
7.1.6 Southeast Asia Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
7.1.7 Australia Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
7.2 Asia Pacific Drugs for Non-small Cell Lung Cancer Market Status by Manufacturers
7.3 Asia Pacific Drugs for Non-small Cell Lung Cancer Market Status by Type (2013-2017)
7.3.1 Asia Pacific Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)
7.3.2 Asia Pacific Drugs for Non-small Cell Lung Cancer Revenue by Type (2013-2017)
7.4 Asia Pacific Drugs for Non-small Cell Lung Cancer Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Drugs for Non-small Cell Lung Cancer Market Status by Countries
8.1.1 Latin America Drugs for Non-small Cell Lung Cancer Sales by Countries (2013-2017)
8.1.2 Latin America Drugs for Non-small Cell Lung Cancer Revenue by Countries (2013-2017)
8.1.3 Brazil Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
8.1.4 Argentina Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
8.1.5 Colombia Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
8.2 Latin America Drugs for Non-small Cell Lung Cancer Market Status by Manufacturers
8.3 Latin America Drugs for Non-small Cell Lung Cancer Market Status by Type (2013-2017)
8.3.1 Latin America Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)
8.3.2 Latin America Drugs for Non-small Cell Lung Cancer Revenue by Type (2013-2017)
8.4 Latin America Drugs for Non-small Cell Lung Cancer Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Drugs for Non-small Cell Lung Cancer Market Status by Countries
9.1.1 Middle East and Africa Drugs for Non-small Cell Lung Cancer Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Drugs for Non-small Cell Lung Cancer Revenue by Countries (2013-2017)
9.1.3 Middle East Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
9.1.4 Africa Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
9.2 Middle East and Africa Drugs for Non-small Cell Lung Cancer Market Status by Manufacturers
9.3 Middle East and Africa Drugs for Non-small Cell Lung Cancer Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)
9.3.2 Middle East and Africa Drugs for Non-small Cell Lung Cancer Revenue by Type (2013-2017)
9.4 Middle East and Africa Drugs for Non-small Cell Lung Cancer Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF DRUGS FOR NON-SMALL CELL LUNG CANCER
10.1 Global Economy Situation and Trend Overview
10.2 Drugs for Non-small Cell Lung Cancer Downstream Industry Situation and Trend Overview
CHAPTER 11 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Drugs for Non-small Cell Lung Cancer by Major Manufacturers
11.2 Production Value of Drugs for Non-small Cell Lung Cancer by Major Manufacturers
11.3 Basic Information of Drugs for Non-small Cell Lung Cancer by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Drugs for Non-small Cell Lung Cancer Major Manufacturer
11.3.2 Employees and Revenue Level of Drugs for Non-small Cell Lung Cancer Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 DRUGS FOR NON-SMALL CELL LUNG CANCER MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Bristol-Myers Squibb
12.1.1 Company profile
12.1.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.1.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
12.2 GlaxoSmithKline
12.2.1 Company profile
12.2.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.2.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.3 Menarini
12.3.1 Company profile
12.3.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.3.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Menarini
12.4 Sanofi
12.4.1 Company profile
12.4.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.4.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Sanofi
12.5 Ziopharm Oncology
12.5.1 Company profile
12.5.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.5.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Ziopharm Oncology
12.6 Alchemia
12.6.1 Company profile
12.6.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.6.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Alchemia
12.7 Amgen
12.7.1 Company profile
12.7.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.7.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Amgen
12.8 Apotex
12.8.1 Company profile
12.8.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.8.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Apotex
12.9 BioMarin Pharmaceutical
12.9.1 Company profile
12.9.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.9.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of BioMarin Pharmaceutical
12.10 CellAct Pharma
12.10.1 Company profile
12.10.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.10.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of CellAct Pharma
12.11 Cerulean Pharma
12.11.1 Company profile
12.11.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.11.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Cerulean Pharma
12.12 Cipla
12.12.1 Company profile
12.12.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.12.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Cipla
12.13 Cornerstone Pharmaceuticals
12.13.1 Company profile
12.13.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.13.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Cornerstone Pharmaceuticals
12.14 Curis
12.14.1 Company profile
12.14.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.14.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Curis
12.15 CytRx
12.15.1 Company profile
12.15.2 Representative Drugs for Non-small Cell Lung Cancer Product
12.15.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of CytRx
12.16 Eli Lilly
12.17 Exelixis
12.18 Fresenius Kabi
12.19 Genentech
12.20 Hikma Pharmaceuticals
12.21 Hospira
12.22 Intas Pharmaceuticals
12.23 Karyopharm Therapeutics
12.24 Kyowa Hakko Kirin
12.25 Ligand Pharmaceuticals
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF DRUGS FOR NON-SMALL CELL LUNG CANCER
13.1 Industry Chain of Drugs for Non-small Cell Lung Cancer
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF DRUGS FOR NON-SMALL CELL LUNG CANCER
14.1 Cost Structure Analysis of Drugs for Non-small Cell Lung Cancer
14.2 Raw Materials Cost Analysis of Drugs for Non-small Cell Lung Cancer
14.3 Labor Cost Analysis of Drugs for Non-small Cell Lung Cancer
14.4 Manufacturing Expenses Analysis of Drugs for Non-small Cell Lung Cancer
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
